Rhythm Pharmaceuticals Eyes Expansion with Strong IMCIVREE Sales and Key Clinical Milestones
Event summary
- IMCIVREE global sales reached $57.3 million in Q4 2025, up 12% sequentially.
- FDA set March 20, 2026 PDUFA goal date for sNDA approval of setmelanotide in acquired hypothalamic obesity (HO).
- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months.
- Company expects topline data from Japanese cohort of setmelanotide Phase 3 trial and EMANATE trial in March 2026.
The big picture
Rhythm Pharmaceuticals is positioning itself for long-term growth by leveraging strong IMCIVREE sales and advancing its clinical pipeline. The company's focus on rare neuroendocrine diseases aligns with broader industry trends toward targeted therapies, but success hinges on securing regulatory approvals and maintaining robust R&D momentum.
What we're watching
- Regulatory Approval
- Whether the FDA will approve setmelanotide for acquired HO by March 20, 2026.
- Clinical Development
- The pace at which topline data from Phase 3 trials will influence investor sentiment.
- Commercial Strategy
- How Rhythm Pharmaceuticals plans to sustain IMCIVREE sales growth amid increasing competition.
Our editorial coverage:
Related topics